Key result
Verapamil reduced major events in patients recovering from acute myocardial infarction, with significant benefit in those without heart failure during the acute phase (HR 0.66; 95% CI 0.47-0.92).
Why the study?
Does verapamil reduce the first major event rate (reinfarction or death) in patients recovering from acute myocardial infarction with and without impaired cardiac function?
RCT (n=1,775)
placebo-controlled
randomized
Does verapamil reduce the first major event rate (reinfarction or death) in patients recovering from acute myocardial infarction with and without impaired cardiac function?
Verapamil reduces major events (reinfarction or death) in post-MI patients without heart failure, and does not appear to have a detrimental effect on major events in those with heart failure.
No takes yet. Share an insight, caveat, or question.
Supports verapamil for secondary prevention post-MI without heart failure; extends calcium channel blocker evidence beyond beta-blockers.
Christian M. Jespersen (1993) conducted an RCT in Acute myocardial infarction (n=1,775). Verapamil vs. Placebo was evaluated on First major event (reinfarction or death) while on trial medication. Verapamil reduced major events in patients recovering from acute myocardial infarction, with significant benefit in those without heart failure during the acute phase (HR 0.66; 95% CI 0.47-0.92).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: